Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Research and development

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

An immunotherapy platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ immunotherapy has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics to Present at DNB Carnegie Conference on ...

Read More
09 March 2026

Nykode Therapeutics to Present New Data and Participate in ...

Read More
03 March 2026

Nykode Therapeutics reports Q4 2025 Financial Results

Read More
25 February 2026

Nykode Therapeutics Announces New Interim Data from the VB-C-03 ...

Read More
24 February 2026

Nykode Therapeutics – Invitation to Q4 2025 Financial Results ...

Read More
11 February 2026

Nykode Therapeutics to Present Interim Data from the VB-C-03 ...

Read More
19 December 2025

Nykode Therapeutics Strengthens Board with the Nomination of Dr. ...

Read More
18 December 2025

Nykode Therapeutics ASA – Notice of Extraordinary General Meeting

Read More
18 December 2025

Nykode Therapeutics reports Q3 2025 Financial Results

Read More
24 November 2025